A retrospective study on the quality of Haemophilus influenzae type b vaccines used in the UK between 1996 and 2004

Human Vaccines

Volumn 3, Issue 5, 2007, Pages 176-182

  Bolgiano, Barbara ^a   Mawas, Fatme ^a   Burkin, Karena ^a   Crane, Dennis T ^a   Saydam, Manolya ^a   Rigsby, Peter ^a   Corbel, Michael J ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Chromatography; Combination vaccines; Conjugate vaccine; H. influenzae; Immunogenicity; Molecular size; Polysaccharide; Tetanus toxoid

Indexed keywords

CARBOHYDRATE; INFLUENZA VACCINE; POLYSACCHARIDE; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG QUALITY; DRUG STABILITY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HAEMOPHILUS INFLUENZAE TYPE B; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOGENICITY; MOLECULAR SIZE; NONHUMAN; RAT; RETROSPECTIVE STUDY; SHELF LIFE; UNITED KINGDOM;

EID: 35348988644     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.3.5.4352     Document Type: Article

References (31)

1. World Health Organization. Recommendations for the production and control of Haemophilus influenzae type b conjugate vaccines. WHO Technical Report Series 2000; No. 897. Annex 1:27-60. (http://www.who.int/biologicals/ publications/trs/areas/vaccines/ influenza/WHO_TRS_897_A1.pdf. (accessed 22 November 2006)).
2. Trotter CL, Ramsay ME, Slack MP. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Communicable Dis and Public Health 2003; 6:55-8.
3. McVernon J, Trotter CL, Slack MPE, Ramsay ME. Trends in Haemophilus influenzae type b infections in adults in England and Wales: Surveillance study. Brit Med J 2004; 329:655-8.
4. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003; 188:481-5.
5. Trotter CL, McVernon J, Andrews NJ, Burrage M, Ramsay ME. Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet 2003; 361:1523-4.
6. McVernon J, Andrews NJ, Slack MPE, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003; 361:1521-23.
7. Halperin SA, Barreto L, Eastwood BJ, Medd L, Guasparini R, Mills E. Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine. Vaccine 1997; 15:295-300.
8. Daum RS, Zenko CE, Given GZ, Ballanco GA, Parikh H, Germino K. Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/ Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered. J Infect Dis 2001; 184:1293-99.
9. Bell E, Heath P, Shackley E, Maclennan N, Diggle L. Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T). Vaccine 1998; 16:637-42.
10. Poolman J, Kaufhold A, De Grave D, Goldblatt D. Clinical relevance of lower Hib response in DTPa-based combination vaccines. Vaccine 2001; 19:2280-5.
11. European Union Invasive Bacterial Infections Surveillance Network. Invasive Haemophilus influenzae in Europe - 2002. February 2004; 1-27, (http://www.euibis.org/documents/2002_ hib.pdf. (accessed 11 April 2007)).
12. Plumb JE, Yost SE. Molecular size characterization of Haemophilus influenzae type b polysaccharide-protein conjugate vaccines. Vaccine 1996; 14:399-404.
13. von Hunolstein C, Parisi L, Recchia S. A routine high-performance size-exclusion chromatography to determine molecular size distribution of Haemophilus influenzae type b conjugate vaccines. Vaccine 1999; 17:118-25.
14. 197 conjugate vaccines. Vaccine 2001; 19:3189-200.
15. Ho MM, Mawas F, Bolgiano B, Lemercinier X, Crane DT, Huskisson R, Corbel MJ. Physico-chemical and immunological examination of the thermal stability of tetanus toxoid conjugate vaccines. Vaccine 2002; 20:3509-22.
16. Mawas F, Newman G, Burns S, Corbel MJ. Suppression and modulation of cellular and humural immune responses to Haemophilus influenzae type B (Hib) conjugate vaccine in Hib-diphtheria-tetanus toxoids-acellular pertussis combination vaccines: A study in a rat model. J Infect Dis 2005; 191:58-64.
17. European Pharmacopoeia: Bacterial Endotoxins. Vol 1. 5th ed. Monograph 2.6.14. Strasbourg: European Pharmacopoeia, 2006.
18. Mawas F, Bolgiano B, Belgrave D, Crane D, Rigsby P, MJ Corbel. International collaborative study to evaluate a candidate international standard for Haemophilus influenzae type b capsular polysaccharide. Final report. Geneva: World Health Organization, Expert Committee on Biological Standardization, 2005, (Report No.: WHO/BS/05.2018).
19. Mawas F, Dickinson R, Douglas-Bardsley A, Xing DKL, Sesardic D, Corbel MJ. Immune interaction between components of acellular pertussis-diphtheria- tetanus (DTaP) vaccine and Haemophilus influenzae b (Hib) conjugate vaccine in a rat model. Vaccine 2006; 24:3505-12.
20. Heath PT, Booy R, Griffiths H, Clutterbuck E, Azzopardi HJ, Slack MPE, Fogarty J, Moloney AC, Moxon ER. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failures in childhood. Clin Infect Dis 2000; 31:973-80.
21. Heath PT, Booy R, McVernon J, Bowen-Morris J, Griffiths H, Slack MPE, Moloney AC, Ramsay ME, Moxon ER. Hib vaccination in infants born prematurely. Arch Dis Child 2003; 88:206-10.
22. Kelly D, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunol 2004; 113:163-74.
23. Johnson NG, Ruggeber JU, Balfour GF, Lee YC, Liddy H, Irving D, Sheldon J, Slack MP, Pollard AJ, Heath PT. Haemophilus influenzae type b re-emergence after combination immunization. Emerg Infect Dis 2006; 12:937-41.
24. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999; 354:2063-8.
25. Cequetti M, Cardines R, Ciofi degli Atti ML, Giufré M, Bella A, Sofia T, Mastrantonio P, Slack M. Presence of multiple copies of the capsulation b locus in invasive Haemophilus influenzae type b (Hib) strains isolated from children with Hib conjugate vaccine failure. J Infect Dis 2005; 192:819-23.
26. Anderson PW, Pichichero MI, Insel RA, Betts R, Eby R, Smith DH. Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b couple to a protein carrier: Structural and temporal requirements for priming in the human infant. J Immunol 1986; 137:1181-6.
27. 197 vaccines: Effect of saccharide size on immunogenicity and interactions with simultaneously administeted vaccines. J Infect Dis 1997; 176:445-55.
28. Peeters CCAM, Tenbergen-Meekes AM, Evenberg DE, Poolman JT, Zegers BJM, Rijkers GT. A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice. J Immunol 1991; 146:4308-14.
29. Wessels MR, Paoletti LC, Guttormsen HK, Michon R, D'Ambra AJ, Kasper DL. Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy. Infect and Immunity 1998; 66:2186-92.
30. Laferrière CA, Sood RK, de Muys JM, Michon F, Jennings HJ. The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity. Vaccine 1997; 15:179-86.
31. Egan W, Frasch CE, Anthony BF. Lot-release criteria, post licensure quality control, and the Haemophilus influenza type b conjugate vaccines. JAMA 1995; 273:888-9.